Boehringer Ingelheim: Renal Insufficiency trials
The registry lists 11 Renal Insufficiency studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 1 10Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney ProblemsCompletedNCT05718843Phase 1Results posted
- A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney ProblemsCompletedNCT05718648Phase 1Results posted
- A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the BodyCompletedNCT03302091Phase 1Results posted
- Afatinib in Subjects With Kidney DysfunctionCompletedNCT02096718Phase 1Results posted
- Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired PatientsTerminatedNCT01957657Phase 1Results posted
- Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal ImpairmentCompletedNCT01164501Phase 3Results posted
- A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney ProblemsCompletedNCT06352411Phase 1
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal FunctionCompletedNCT02191228Phase 1
- Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of NevirapineCompletedNCT02184091Phase 1
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal ImpairmentCompletedNCT02182024Phase 1
- The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy SubjectsCompletedNCT02172339Phase 1